Nanotek Biologics Deal Gives Green Cross Route To Russia
This article was originally published in PharmAsia News
Executive Summary
Following its entry into North America and China, Green Cross is set to make inroads into the rapidly growing Russian pharmaceutical market through a strategic partnership with Nanolek to commercialize the South Korean biopharmaceutical company’s biologics.